#1 Clinical Trials Search in Europe

PIPOTIAZINE

Clinical trials involving the antipsychotic medication Pipotiazine are shedding light on important treatment strategies for individuals with schizophrenia spectrum disorders. One significant ongoing trial is examining whether reducing antipsychotic medication doses, including Pipotiazine, might benefit certain patients who have achieved clinical stability. This research aims to address patients’ frequent requests to lower their medication dosage while providing clinicians with evidence-based guidance on when dose reduction might be appropriate versus when maintaining current dosages is preferable. The study takes a personalized medicine approach by considering patients’ specific psychotic phenotypes (cycloid psychosis vs. non-cycloid psychosis) to determine which patients might respond better to dose reduction strategies.

Table of Contents

What is Pipotiazine?

Pipotiazine (also known as Pipotiazine palmitate) is a first-generation antipsychotic medication. It belongs to a group of medications called “typical antipsychotics” or “conventional antipsychotics.” These are older medications developed to treat various mental health conditions, particularly those involving psychosis.[1] First-generation antipsychotics like Pipotiazine work primarily by blocking dopamine receptors in the brain, which helps control symptoms of psychosis.

Medical Uses

Pipotiazine is primarily used to treat disorders within the schizophrenia spectrum. Based on the clinical trial information, these disorders include:[1]

  • Schizophrenia – A serious mental disorder characterized by distortions in thinking, perception, emotions, language, sense of self, and behavior
  • Schizophreniform disorder – Similar to schizophrenia but lasting less than six months
  • Schizoaffective disorder – A condition where a person experiences a combination of schizophrenia symptoms and mood disorder symptoms
  • Brief psychotic episodes – Short periods of psychotic behavior often triggered by extreme stress

The medication helps manage symptoms such as hallucinations, delusions, disorganized thinking, and other psychotic symptoms that characterize these conditions.[1]

Treatment Strategies

According to the clinical trial data, there are two main treatment strategies being studied with Pipotiazine and other antipsychotics:[1]

  1. Dose Reduction Strategy – This involves gradually reducing the patient’s usual antipsychotic dose to levels lower than those typically recommended by official guidelines. This strategy is being explored as many patients express a desire to reduce or stop their antipsychotic medication once they achieve clinical stability.
  2. Maintenance Treatment Strategy – This involves maintaining the patient’s antipsychotic dose in accordance with the officially recommended dosages.

The clinical trial is specifically investigating whether different types of patients (based on their psychotic phenotype – which means the observable characteristics of their illness) might respond differently to these two strategies.[1]

Patient Monitoring

When taking Pipotiazine, patients in the clinical trial undergo regular monitoring to assess their progress and ensure their safety:[1]

  • Regular follow-up visits (monthly for four months, then every two months)
  • Completion of self-questionnaires and cognitive tests by the patient and their caregiver
  • Blood samples taken at specific intervals to measure medication levels in the blood
  • Assessment of functional remission using the Personal and Social Performance Scale (a tool that measures how well a person is functioning in their daily life)

This comprehensive monitoring helps healthcare providers track how well the medication is working and whether any adjustments are needed to the treatment plan.[1]

Cycloid Psychosis vs. Non-Cycloid Psychosis

The clinical trial is exploring whether patients with different types of psychosis respond differently to dose reduction versus maintenance treatment. The two types being studied are:[1]

  • Cycloid Psychosis (CP) – This is a form of psychosis characterized by sudden onset, rapidly changing symptoms, and often good recovery between episodes. Symptoms can include confusion, mood changes, and hallucinations that come and go in a cyclical pattern.
  • Non-Cycloid Psychosis (Non-CP) – This refers to other forms of psychosis that don’t follow the cyclical pattern seen in cycloid psychosis.

The research hypothesis is that patients with cycloid psychosis might benefit more from dose reduction compared to those with non-cycloid psychosis.[1]

Considerations for Patients

If you are taking Pipotiazine or another antipsychotic medication and are interested in potentially reducing your dose, there are several important points to consider:[1]

  • Never adjust your medication without medical supervision – The clinical trial emphasizes the importance of proper medical guidance when reducing antipsychotic doses
  • Individual response varies – The study is specifically looking at how different types of patients respond to dose reduction, suggesting that what works for one person may not work for another
  • Regular monitoring is essential – Frequent follow-ups with healthcare providers help ensure that any changes in symptoms are detected early
  • Blood tests may be needed – To accurately assess medication levels and effectiveness
  • Support from caregivers is valuable – The study involves input from caregivers, highlighting their important role in the treatment process

The clinical trial acknowledges that many patients wish to reduce their antipsychotic medication once they’ve achieved stability, but also notes that psychiatrists have been reluctant to do so because “the method for safely reducing or stopping antipsychotic treatment remains poorly understood.” This research aims to provide better guidance on this important question.[1]

Study Aspect Details
Clinical Trial Identifier NCT07152184
Primary Purpose Compare antipsychotic dose reduction vs. maintenance treatment in schizophrenia spectrum disorders using a personalized medicine approach
Medications Studied Multiple antipsychotics including Pipotiazine/Pipotiazine palmitate (first-generation), along with other first and second-generation antipsychotics
Study Groups Four groups based on phenotype and treatment strategy: CP-dose reduction; CP-dose maintenance; non-CP-dose reduction; non-CP-dose maintenance
Participants 288 adults (18-60 years) with schizophrenia spectrum disorders
Study Duration 24-month follow-up period with 14 visits
Primary Outcome Percentage of patients achieving functional remission (Personal and Social Performance Scale score >70) at 24 months
Assessment Methods Questionnaires, cognitive tests, blood samples, and clinical evaluations
Main Hypothesis The benefit of dose reduction vs. maintenance will be greater in cycloid psychosis patients than in non-cycloid psychosis patients

FAQ

  • What is the main purpose of the clinical trial involving Pipotiazine? The main purpose of this clinical trial is to investigate whether it's safe and effective to reduce antipsychotic medication doses (including Pipotiazine) in patients with schizophrenia spectrum disorders who have achieved clinical stability. The study specifically aims to determine if the benefit of dose reduction compared to dose maintenance varies depending on the patient's psychotic phenotype (whether they have cycloid psychosis or non-cycloid psychosis). This responds to patients' frequent requests to reduce their medication while providing clinicians with evidence-based guidance.
  • How is Pipotiazine being used in this clinical trial? In this trial, Pipotiazine (specifically Pipotiazine palmitate/Pipotiazine) is one of several antipsychotic medications being studied. Depending on which study arm patients are assigned to, they will either have their Pipotiazine dose gradually reduced to levels below those typically recommended in official guidelines, or they will maintain their usual dose according to standard recommendations. The study is comparing these two approaches to determine which might be better for different types of patients.
  • What types of patients are being included in this Pipotiazine study? The study includes adults aged 18 to 60 who have been diagnosed with a schizophrenia spectrum disorder, which includes schizophrenia, schizophreniform disorder, schizoaffective disorder, or brief psychotic episode. Patients are further classified based on whether they have cycloid psychosis or non-cycloid psychosis. The study aims to include 288 patients total who will be followed for 24 months.
  • What are the different treatment groups in this Pipotiazine clinical trial? There are four treatment groups in this study: 1) Patients with Cycloid Psychosis receiving dose reduction (CP-DR), 2) Patients with Cycloid Psychosis maintaining their current dose (CP-MT), 3) Patients with Non-Cycloid Psychosis receiving dose reduction (Non-CP-DR), and 4) Patients with Non-Cycloid Psychosis maintaining their current dose (Non-CP-MT). Patients are randomly assigned to either the dose reduction or maintenance strategy after their psychosis type is determined.
  • How is the effectiveness of Pipotiazine treatment being measured in this trial? The primary way the effectiveness is being measured is by looking at functional remission, defined as a score greater than 70 on the Personal and Social Performance Scale (PSP) after 24 months of follow-up. This assessment measures how well patients are functioning in their daily lives. These evaluations are conducted by a team that doesn't know which treatment group the patient is in (called blind assessment) to ensure unbiased results. The study also includes other assessments through questionnaires completed by patients and caregivers, as well as blood samples to measure medication levels.

Ongoing Clinical Trials on PIPOTIAZINE

  • Study on Reducing Antipsychotic Dose vs. Maintenance Treatment for Patients with Schizophrenia Using Haloperidol Decanoate, Risperidone, and Amisulpride

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    France

Glossary

  • Antipsychotic: A type of medication used to manage symptoms of psychosis, such as delusions or hallucinations, commonly prescribed for conditions like schizophrenia. Pipotiazine is a first-generation antipsychotic medication.
  • Schizophrenia Spectrum Disorder (SSD): A group of mental health conditions characterized by abnormalities in thinking, perception, emotions, language, sense of self, and behavior. Includes schizophrenia, schizophreniform disorder, schizoaffective disorder, and brief psychotic episodes.
  • Pipotiazine: A first-generation (typical) antipsychotic medication used to treat schizophrenia and other psychotic disorders. It's available in forms including Pipotiazine palmitate, which is a long-acting injectable formulation.
  • Cycloid Psychosis (CP): A type of psychotic disorder characterized by sudden onset, rapid shifts between symptoms, and often better outcomes than other forms of psychosis. In this study, patients are categorized as having either cycloid psychosis or non-cycloid psychosis.
  • Dose Reduction Strategy: A treatment approach where medication doses are gradually lowered to levels below standard recommendations. In this study, this strategy is being compared to maintenance treatment to determine which patients might benefit from lower doses.
  • Maintenance Treatment Strategy: A treatment approach where medication doses are kept stable at currently effective levels. This is the standard approach for patients who have achieved stability on their current medication regimen.
  • Marketing Authorization (AMM): The official approval that allows a medication to be sold with specific dosing guidelines. In this study, some patients are receiving doses lower than those officially recommended in these guidelines.
  • Randomization: A process in clinical trials where participants are assigned by chance (like a coin flip) to different treatment groups. This helps ensure that the groups are similar and reduces bias in the results.
  • Personal and Social Performance Scale (PSP): A clinical tool used to measure how well a person is functioning in their daily life across various domains. In this study, a score above 70 indicates functional remission, which is the main outcome being measured.
  • Functional Remission: The recovery of social and occupational functioning to a normal or near-normal level. In this study, it's defined specifically as scoring above 70 on the Personal and Social Performance Scale.
  • First-generation Antipsychotics: The earlier class of antipsychotic medications (also called typical antipsychotics) that includes Pipotiazine, chlorpromazine, flupentixol, haloperidol, levomepromazine, loxapine, and zuclopenthixol.
  • Second-generation Antipsychotics: A newer class of antipsychotic medications (also called atypical antipsychotics) that includes amisulpride, aripiprazole, olanzapine, quetiapine, and risperidone.
  • Blinded Assessment: A method where the person evaluating outcomes doesn't know which treatment group the patient belongs to. This helps prevent bias in the assessment. In this study, the Dreams-Phen evaluation team performs blinded assessments.
  • Personalized Medicine Approach: A medical model that tailors treatment decisions to individual patients based on their predicted response or risk of disease. This study applies this concept by investigating whether treatment strategies should differ based on a patient's specific psychotic phenotype.

References

  1. https://clinicaltrials.gov/study/NCT07152184